Skip to main content
Top
Literature
1.
go back to reference Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L et al (2016) Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374:1243–1252CrossRef Genovese MC, Kremer J, Zamani O, Ludivico C, Krogulec M, Xie L et al (2016) Baricitinib in patients with refractory rheumatoid arthritis. N Engl J Med 374:1243–1252CrossRef
2.
go back to reference Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. (2020) Baricitinib plus remdesivir for hospitalized adults with covid-19. N Engl J Med [Internet] 2020 [cited 2021 Jul 4]; Available from: https://www.nejm.org/doi/https://doi.org/10.1056/NEJMoa2031994 Kalil AC, Patterson TF, Mehta AK, Tomashek KM, Wolfe CR, Ghazaryan V, et al. (2020) Baricitinib plus remdesivir for hospitalized adults with covid-19. N Engl J Med [Internet] 2020 [cited 2021 Jul 4]; Available from: https://​www.​nejm.​org/​doi/​https://​doi.​org/​10.​1056/​NEJMoa2031994
3.
go back to reference Holtzman NG, Im A, Ostojic A, Curtis LM, Parsons-Wandell L, Nashed J et al (2020) Efficacy and safety of baricitinib in refractory chronic graft-versus-host disease (cGVHD): preliminary analysis results of a phase 1/2 study. Blood 136:1–1CrossRef Holtzman NG, Im A, Ostojic A, Curtis LM, Parsons-Wandell L, Nashed J et al (2020) Efficacy and safety of baricitinib in refractory chronic graft-versus-host disease (cGVHD): preliminary analysis results of a phase 1/2 study. Blood 136:1–1CrossRef
4.
go back to reference Lu X, Tang LV, Wang H-F, You Y, Wang Y-D, Hu Y et al (2021) The great challenge of managing recipients of hematopoietic stem cell transplantation combined with COVID-19. Bone Marrow Transplant 56:696–700CrossRef Lu X, Tang LV, Wang H-F, You Y, Wang Y-D, Hu Y et al (2021) The great challenge of managing recipients of hematopoietic stem cell transplantation combined with COVID-19. Bone Marrow Transplant 56:696–700CrossRef
Metadata
Title
Baricitinib: Two Birds with One Stone
Authors
Fen Saj
Smita Kayal
Biswajit Dubashi
Prasanth Ganesan
Publication date
24-01-2022
Publisher
Springer India
Published in
Indian Journal of Hematology and Blood Transfusion / Issue 3/2022
Print ISSN: 0971-4502
Electronic ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-022-01521-5

Other articles of this Issue 3/2022

Indian Journal of Hematology and Blood Transfusion 3/2022 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine